Eupraxia Pharmaceuticals Inc. — Investor Relations & Filings

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted, extended-release therapies using its proprietary drug delivery platform, Diffusphere™. This technology is engineered to optimize local, controlled drug delivery directly to diseased tissues, aiming to maximize efficacy and minimize systemic side effects. Eupraxia addresses therapeutic areas with significant unmet medical needs, particularly in gastrointestinal and musculoskeletal diseases. The company's lead product candidate, EP-104GI, is currently in Phase 2 clinical trials for the treatment of Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The Diffusphere platform is designed to potentially offer long-term relief with fewer doses across various conditions, including inflammatory diseases, oncology, and pain.